Introduction
Non-random, clonal chromosomal deletions are frequently found in bone marrow cells of patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). This is especially true in patients with secondary MDS/AML, clonal disorders that evolve in patients with a prior history of exposure to therapeutic or environmental toxins, particularly alkylating agents. [1] [2] [3] In view of the substantial evidence that deleted chromosomal material in neoplastic cells commonly contains tumor suppressor loci, 4 the loss of this material in MDS/AML suggests that tumor suppressor genes of particular relevance to the control of hematopoietic cells are located on these chromosomes.
While some tumor suppressor gene (TSG) haploinsufficiencies are carcinogenic, 5 most often, the TSG locus residing on the retained chromosome is inactivated as well and the tumor cells have lost heterozygosity through somatic mutation. 6 Many of the genes located in deleted regions, where gene function has been defined, encode proteins either directly or indirectly involved in transducing environmental cues for mitotic inhibition or apoptosis. 7, 8 Consequently, a lack of both tumor suppressor alleles, through loss of heteroz- ygosity (LOH), results in the subversion of modulatory growth control signals. Therefore, it follows that cells transformed by inactivation of such genes will be insensitive to one or more extracellular cues that control mitotic arrest or programmed cell death. Examples of this have been previously demonstrated in tumor-derived tissue. For example, ablation of transforming growth factor-beta (TGF␤) induced cell cycle arrest can result from loss of either p21/WAF1/Cip1 7 or p27KIP1 8 function.
Selection
While the LOH model has enormous scientific support it is, in our view, incomplete. We believe that it presumes, but does not clarify, the important role of selective pressure in the process of clonal evolution. Clonal selection is a fundamental tenet of biology in both prokaryotes (eg the evolution and proliferation of antibiotic resistant strains of bacteria) and eukaryotes (eg that which occurs in the evolution of multiple drug resistant forms of cancer). In early leukemogenesis, when a single, phenotypically normal stem cell inactivates or deletes its only remaining functional allele for a particular tumor suppressor gene, selective pressure is critical to permit the outgrowth of that mutant clone. If inactivation of such a mitotic inhibition pathway occurred in a normal stem cell, it could lead to a proliferative advantage over its neighbors. However, this would be the case only if the inhibitory signaling pathway of interest was chronically or repetitively active and as a consequence, served to suppress the replication and/or survival of the non-mutant clones. One clear selective force for such events could be a stem cell pool in which every member responded in an exaggerated manner to physiologically relevant levels of mitotic inhibitory factors. Hematopoietic progenitor and stem cells from children with Fanconi anemia (FA) and FA knockout mice are unambiguous examples of this. Colony-forming units (CFU) from bone marrow of children with the C complementation group (FA-C) and knockout mice with disruptions of the group C gene (FANCC) are hypersensitive to interferon gamma (IFN␥) and tumor necrosis factor alpha (TNF␣).
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Here, we propose a model for the evolution of neoplastic clones in children with Fanconi anemia. We also argue that MDS in FA patients is a de facto model of secondary MDS in non-FA adults (Table 1 ). In view of the observations of Morley et al 12 who studied busulfan-treated mice several years ago, exposure of adults to alkylating agents may lead to chronic stem cell injury (perhaps akin to that seen in FA), thereby creating a similar selective force for clonal evolution in struggling stem cells. In our view, there is a real possibility that progenitors and stem cells from leukemogen-treated adults share certain functional abnormalities with those from FA bone marrow. Experiments testing this idea are now being carried out in our laboratory.
FA and the apoptotic phenotype
Fanconi anemia is a rare, autosomal recessive disorder consisting of skeletal abnormalities, café au lait spots, hypersensitivity to cross-linking agents, 13, 14 bone marrow failure, 15 and a high frequency of myelodysplasia and acute myelogenous leukemia. 16, 17 Acute myeloid leukemia is the most common neoplasm that develops in patients with FA, although the risk of cancer in general is increased. 16, 18 The prevalence of acute myeloid leukemia in FA is substantial and estimated to be 15 000 times greater than that of the general population. 19, 20 Treatment in these patients is extraordinarily difficult, in part because of the inherent sensitivity of all FA cells to certain chemotherapeutic agents.
To date, the genes for three FA complementation groups (of eight, represented as FA-(A-H)) have been cloned. They are FANCA (chromosome 16q24.3), FANCC (9q22.3), and FANCG (9p13). [21] [22] [23] Although the Fanconi anemia gene products (at least the C protein) play obvious roles in the growth and differentiation of normal bone marrow (bone marrow is the only organ that universally fails in children with FA) the exact function of the protein products of these genes is unknown. In an effort to better understand the possible FA gene functions, a murine model for FA-C has been established by targeted embryonic stem-cell disruption. 9 Progenitor cells from these knockout mice exhibit hypersensitivity to crosslinking agents similar to that found in Fanconi anemia patients. 9 Of more relevance to our model of selective pressure, cells from these mice are also hypersensitive to biological factors that ordinarily serve as environmental cues for mitotic arrest or programmed cell death. Specifically, we have shown that the mice demonstrate hypersensitivity to the inhibitory effects of IFN␥ in vitro and in vivo. 9 Haneline et al has recently reported hypersensitivity to IFN␥, TNF␣ and the chemokine MIP1␣ 11 and reduced repopulating potential in FANCC stem cells, 24 a phenomenon that is quite compatible with apoptosis in stem cells or their immediate progeny.
Given these exaggerated apoptotic responses in human FA-C progenitor cells, the high incidence of bone marrow failure is not surprising. 9 A number of findings support this notion. First, strong evidence exists that intramedullary IFN␥ release may be pathophysiologically involved in the development of acquired aplastic anemia. 10 Secondly, low levels of IFN␥ prime the fas pathway in FA-C cells. 10 Finally, a high fraction of CD34
+ cells from children with FA constitutively express both fas 25 and IRF-1. 10 In effect, progenitor cells from FA patients 'act as if' they have been stimulated with interferon, just as cells from Von Hippel-Lindau syndrome patients 'act as if' they are hypoxic.
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FA and fas
The fas protein (CD95) is a member of the tumor necrosis factor (TNF) super-family. 27 Its intracellular portion contains a region known as the 'death domain' and is required for activation of the signaling pathway (after fas ligand (fas-L) binding) that leads to caspase activation and apoptosis. 28, 29 Freshly isolated normal CD34
+ cells do not express fas but fas is induced by IFN␥ stimulation. 10, 30, 31 However, a higher fraction of CD34
+ cells from children with FA express fas. 25 In our hands, the highly suppressive effects of IFN␥ in FA progenitor cells was abrogated by the addition of neutralizing antibodies to fas, and the toxicity of IFN␥ was augmented by the addition of an agonistic fas antibody. 10 We have used the term 'fas priming' to describe the state of heightened responsiveness to fas ligation. 32 These studies confirm an important role of the fas pathway in the apoptotic phenotype of FA progenitor cells, observations supported by findings that transgene overexpression of human FANCC cDNA protects murine progenitor cells from fas-induced cell death. 33 
Cytogenetic abnormalities in Fanconi anemia hematopoietic cells
Cytogenetic abnormalities identical to those found in patients with secondary MDS/AML have been noted in bone marrow aspirates of FA patients including 5q−, 34- Abnormalities of chromosome 1 were also quite prevalent in this cohort (43%). It is tempting to attribute clonal evolution simply to a random, mutational process derivative of the widely accepted chromosomal instability in FA. In our view, however, while this force likely plays a part, other cooperative factors play a critical role as well.
The Fanconi anemia complementation group C gene or FANCC is ubiquitously expressed. 22 If clonal evolution occurred stochastically in all somatic cells in children with FA, then one would expect to see neoplastic disorders that were evenly distributed across different organ systems. This is not the case. While epithelial cancers do occur, the dominant clonal neoplastic disorders in children with FA are MDS and AML. We argue that the cooperative factor in leukemogenesis is the selective pressure created in stem cells and progenitors by virtue of the FA mutation itself. These mutations (at least those found in children with the C complementation group) clearly result in exaggerated apoptotic responses via heightened responsiveness to fas-mediated signaling. 10 Taken from the teleological view of stem cells at high risk of death, protective mutations would involve precisely the gene products that transduce the aberrant signal in the apoptotic pathway. This could be through gene conversion at the Fanconi locus itself (a phenomenon that occurs in nature, resulting in mosaicism) 42 or by inactivation of proteins that normally connect hematopoietic cells to the apoptotic response. The strongest evidence in support of this model in non-FA MDS/AML is found in work on human chromosome 5q in hematopoietic cells. 43 
Chromosomal deletions and loss of function mutations
Chromosomal deletions are a common finding in hematopoietic cells from MDS and AML patients. Bone marrow cells of 40-90% of MDS/AML patients bear cytogenetic abnormalities. 6 In keeping with the Knudson model 44 it is widely presumed that the deleted material contains tumor suppressor loci and that the remaining alleles are at risk for inactivating mutations. In conditions with mutator phenotypes or chromosomal instability (such as Fanconi anemia) the machinery is in place for the early inactivation of the remaining locus.
Chromosomal abnormalities in MDS/AML are quite diverse but non-random. Characteristic aberrations include monosomies 5 and 7, and deletions of 5q, 7q and 20q.
6,45-47 Subsets of MDS/AML patients have a very high incidence of clonal chromosomal abnormalities including patients with secondary AML 3,48 and children with MDS/AML arising from a background of Fanconi anemia. 16, 37, 49 Patients whose MDS/AML follows treatment with cross-linking agents for other malignancies have a high incidence of deletions. In a cohort of 257 secondary MDS/AML patients ascertained over a 26-year period at the University of Chicago, approximately 94% were found to bear clonal chromosomal abnormalities. 50 Of these, the two most common were monosomy 7 (29%) and 5q deletion (20%). Together, abnormalities of chromosomes 5 and 7 were found in 71% of cases. Common cytogenetic abnormalities identical to those noted in secondary MDS/AML are also found in the myelodysplastic and leukemic marrows of patients with Fanconi anemia.
5q− and IRF-1 as models
If one were to design inactivating mutations that spare Fanconi anemia stem cells, one would simply inactivate genes encoding factors that transduce apoptotic signals. This is especially relevant in cells that have engaged one or more of the mitotic inhibitory factors to which they are hypersensitive (or perhaps, a factor that the cell inappropriately acts as if it has engaged). Loss of the long arm of chromosome 5 (5q−) and monosomy 5 are less common cytogenetic findings in patients with Fanconi anemia though common in secondary MDS/AML. Interferon response factor-1 (IRF-1) is encoded on chromosome 5q31.1, 43, 51 is necessary for the transduction of an apoptotic response to IFN␥ in progenitor cells, 52 and functions as a tumor suppressor gene. 53 Ordinarily, IRF-1 is inducible (by IFN␥, for example). In FA cells, it is expressed constitutively and low doses of IFN␥ are capable of increasing its expression even further. 54 IRF-1 is itself a transcription factor that binds to an element in the promoters of interferon responsive genes and enhances their expression. 55 The overall biological effect of IRF-1 expression in progenitor cells is growth inhibition and/or apoptosis.
In 1993 Willman and colleagues 43 confirmed genomic loss of IRF-1 via Southern analysis and fluorescent in situ hybridization (FISH) in a sub-population of blasts from patients with chromosome 5q− related MDS/AML. All patients demonstrated reductions of IRF-1 signals on Southern blots probed with the IRF-1 cDNA. 43 This reduction was in proportion to the number of undifferentiated blasts and 5q− clones in each specimen. Additionally, a sub-population of the individuals studied had a significant number of cells with no IRF-1 signal at all by FISH. Since that time, others have found that IRF-1 is not always lost and in some cases the locus is retained on the deleted 5q. 56, 57 However, it is likely that IRF-1 function can be lost in other ways.
Is structural loss of IRF-1 the culprit in secondary MDS/AML? The work by Willman and colleagues 43 indicates that this may play a role in some patients. However, this is likely not the case in FA. Functional loss of IRF-1 (or a similarly acting protein) is a more likely possibility. There are IRF-1-related lesions that do not depend upon gross deletion of 5q material although they potentially implicate abnormal function of IRF-1. 58, 59 For example, Harada et al 58 have demonstrated that transcriptional skipping of exons 2 and 3 of IRF-1 can be found in hematopoietic cells from AML and MDS patients. We expect that other mechanisms (failure of transcriptional activation or accelerated rates of mRNA decay for example) will be discovered in MDS/AML cells that can account for reduced IRF-1 production or function in patients with no detectable abnormality of 5q or IRF-1. Such studies are currently being carried out in our laboratory.
Interdiction of IRF-1 expression in interferon-treated normal progenitor cells not only abrogates the growth inhibitory response, but converts it to a growth-enhancing response. 52 We have had an opportunity to test the notion that IFN␥ responses might be reversed in colony-forming units (CFU) from the marrow of patients with MDS. In some cases, progenitor cells with no known structural abnormalities of the IRF-1 chromosomal region on 5q have exhibited such 'paradoxical', stimulatory growth curves (Figure 1 ). Whether IRF-1 activity is lost in these cells is as yet unknown.
Evolution of leukemic clones from bone marrow failure states
Functional inactivation of both loci for IRF-1 predicts not only the loss of an apoptotic response in interferon-treated cells but also the conversion of IFN␥ to a de facto growth factor. 52 The LOH demonstrated at the IRF-1 locus serves as an instructive model for the outgrowth of abnormal clones in MDS and AML and likely derives from the subversion of a mitotic inhibitory pathway that normally controls stem and progenitor cell replication. In the pro-apoptotic context of FA, a hematopoietic stem cell that experienced this type of deletion would have an enormous selective advantage for growth and production of daughter cells because: (1) it would proliferate in response to IFN␥ exposure and (2) non-deleted cells exposed to IFN␥ would undergo apoptosis (Figure 2 ).
Early causal events (anti-apoptotic) vs late (apoptotic) phenomena in MDS cells
There has been much work published on the apoptotic activity of bone marrow cells in patients with MDS. Raza and colleagues 60 have reported that a high fraction of bone marrow cells undergo programmed cell death in patients with myelodysplasia. Given that myelodysplastic syndromes are known to be disorders of ineffective hematopoiesis, these findings are Variable responses of CD34 + bone marrow cell exposure to IFN␥. Bone marrow derived CFU-GM progenitors from normal volunteers (̆) (n = 9) exhibit a dose-dependent inhibition in colonyforming capacity with increasing concentrations of IFN␥. Progenitor cells from a child with Fanconi anemia (̄) exhibit IFN␥ hypersensitivity. In contrast, certain populations of MDS/AML patients demonstrate insensitivity (í) (a 78-year-old male with secondary AML and monosomy 7) or growth stimulation (b) (a 72-year-old male with MDS and a balanced translocation t(2;5)(q22;q15) over an identical range of IFN␥ concentrations. All curves represent mean (± s.d.) CFU-GM growth expressed as percent control colony growth (no interferon) in methylcellulose cultures containing Steel factor (50 ng/ml), IL-3 (10 ng/ml) and erythropoietin (2 U/ml). In the individual patients, means were calculated from colony counts in triplicate plates at each IFN␥ dose. not surprising. In fact, hematopoietic disorders other than myelodysplasia, including non-neoplastic diseases, can demonstrate a similar increase in apoptotic cells. 61, 62 We are interested in clonal stem cell evolution. In that regard, we must emphasize that in fully evolved MDS marrow, cells in the progenitor pool are not undergoing apoptosis. 63 Indeed, if primitive stem and progenitor cells were undergoing high rates of programmed cell death they would have no clonal advantage whatsoever. In this review, we have focused specifically on the earliest genetic events that occur in stem cells that later lead to MDS and those forces required to set the stage for the emergence of a dominant clone. We have not addressed the process by which more differentiated dysplastic daughter cells of such clones die. 
Conclusion
Because of the shared links of alkylating agent exposure (secondary AML) and alkylating agent sensitivity (Fanconi anemia) as well as unique cytogenetic abnormalities found in common between patients with secondary MDS/AML and individuals with Fanconi anemia, we believe that the evolution of FA to MDS/AML is a paradigm of secondary MDS/AML in non-FA patients. The evolution of myelodysplastic syndromes and acute myelogenous leukemia in FA patients serves as a model system for investigators studying the evolution of certain hematopoietic disorders. The model begs a set of critically important questions for investigators seeking to better understand early molecular steps in the evolution of leukemic clones. What genes are involved in MDS associated with monosomy 7 (and other common chromosomal abnormalities) and do their products influence expression or function of IRF-1? What sorts of lesions do the 'normal' alleles develop that result in their inactivation and are they heritable? Do individuals at risk for secondary AML have a pro-apoptotic phenotype (as do FA patients) prior to clonal evolution and if so, what signaling pathways are involved? Can the risk of MDS/AML in FA patients be reduced with effective gene therapy? Finally, if gene therapy does not reduce the incidence of clonal evolution in Fanconi anemia, do the evolving leukemic clones occur in the corrected or uncorrected stem cells? The donation of hematopoietic and non-hematopoietic cells from children with Fanconi anemia will continue to serve as key components in studies designed to answer these questions. Additional knockout mice with nullizygous mutations at other FA complementation group loci are certain to be valuable resources. The answers to these and related questions will influence our comprehension of myeloid leukemogenesis not only in patients with FA but those whose myeloid leukemia develops notwithstanding perfectly functional FA genes.
